Orphazyme20.jpg

Outlook

OUTLOOK

OUTLOOK

For the full-year 2022, we anticipate a loss from continuing operations in the range DKK 40 – 45 million and a positive result from discontinued operations relating to the Sale of Assets to KemPharm of DKK 87.4 million. We expect to end 2022 with more than DKK 30 million in cash and equivalents.